Tudor Investment Corp ET AL Takes $334,000 Position in Enliven Therapeutics, Inc. $ELVN

Tudor Investment Corp ET AL purchased a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 16,303 shares of the company’s stock, valued at approximately $334,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ELVN. Vestal Point Capital LP raised its holdings in Enliven Therapeutics by 364.0% during the third quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock worth $23,745,000 after purchasing an additional 910,000 shares during the last quarter. TCG Crossover Management LLC acquired a new position in Enliven Therapeutics during the second quarter worth $9,990,000. Duquesne Family Office LLC raised its holdings in Enliven Therapeutics by 104.6% during the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after purchasing an additional 484,405 shares during the last quarter. Marshall Wace LLP raised its holdings in Enliven Therapeutics by 2,886.9% during the second quarter. Marshall Wace LLP now owns 333,333 shares of the company’s stock worth $6,687,000 after purchasing an additional 322,173 shares during the last quarter. Finally, Candriam S.C.A. raised its holdings in Enliven Therapeutics by 46.3% during the third quarter. Candriam S.C.A. now owns 609,352 shares of the company’s stock worth $12,473,000 after purchasing an additional 192,702 shares during the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Enliven Therapeutics

In related news, Director Richard A. Heyman sold 1,230 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total value of $32,201.40. Following the completion of the transaction, the director directly owned 22,647 shares in the company, valued at approximately $592,898.46. This represents a 5.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Joseph P. Lyssikatos sold 20,000 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $26.75, for a total value of $535,000.00. Following the completion of the transaction, the insider owned 745,188 shares of the company’s stock, valued at $19,933,779. The trade was a 2.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 37,460 shares of company stock worth $1,041,104. 25.90% of the stock is currently owned by insiders.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN opened at $45.34 on Friday. Enliven Therapeutics, Inc. has a 1 year low of $14.78 and a 1 year high of $46.31. The firm’s 50 day moving average price is $32.79 and its 200 day moving average price is $25.15. The firm has a market cap of $2.71 billion, a P/E ratio of -24.38 and a beta of 0.26.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). As a group, equities analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ELVN. Mizuho lifted their price objective on Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a report on Wednesday, March 25th. HC Wainwright lifted their price objective on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Wall Street Zen cut Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, January 21st. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $43.40.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.